Patient Information Website
Click here to access
LUVOX CR information for
patients.
Prescribing Information
Download the full
prescribing information.
Social Anxiety Disorder Questionnaire
The Mini-SPIN
"Social anxiety disorder (SAD) is widely underrecognized and underdiagnosed. The Mini-SPIN is a brief 3-item screening tool that can be useful in psychiatric and primary care settings to assist in identifying patients with the generalized type of SAD. It is a validated instrument consisting of items derived from the larger 17-item Social Phobia Inventory (SPIN), which were found to have optimum efficiency when compared to a clinically established diagnosis. A score of 6 or greater is suggestive of generalized SAD, but as with most tests, false positives and false negatives can be found. Therefore a full clinical evaluation is recommended before ruling in or ruling out a diagnosis of SAD."
Jonathan R. T. Davidson, MD
Author of Mini-SPIN
Scoring
Patient responses are rated on a scale of 0 (not at all) to 4 (extremely) on each question. A total score of ≥6 may be associated with an increased risk of having SAD. If a patient's score is suggestive of SAD, further evaluation should be considered before confirming the diagnosis[1]
Please indicate how much the following problems have bothered you during the past week. Mark only one box for each problem, and be sure to answer all items.
Source: [1]
Click submit to find out your score.
Once-A-Day LUVOX CR® (fluvoxamine maleate) Extended-Release Capsules are indicated for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD).
Important Safety Information
CONTRAINDICATIONS
The use of alosetron, tizanidine, thioridazine, or pimozide with LUVOX CR Capsules is contraindicated. The use of MAO inhibitors in combination with LUVOX CR Capsules, or within 14 days of discontinuing treatment with LUVOX CR Capsules, is contraindicated (see WARNINGS and PRECAUTIONS). LUVOX CR Capsules are also contraindicated in patients with a history of hypersensitivity to fluvoxamine maleate or any of its excipients.
ADVERSE EVENTS
In clinical trials, the most commonly observed adverse events with an incidence of ≥5% and at least twice that of placebo were nausea, somnolence, asthenia, diarrhea, anorexia, tremor, and sweating. Overall, these side effects were mild to moderate in severity and transient in nature. Other common adverse events (≥5% and at least twice that of placebo) included abnormal ejaculation and anorgasmia.
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of LUVOX CR® (fluvoxamine maleate) Extended-Release Capsules or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. LUVOX CR Capsules are not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)
Please see full prescribing information, including boxed warning, for LUVOX CR.
References:
- ^ Connor KM, Kobak KA, Churchill LE, et al. Mini-SPIN: a brief screening assessment for generalized social anxiety disorder. Depress Anxiety. 2001;14:137-140.
LUVOX CR is a registered trademark of Solvay Pharmaceuticals, Inc.
© 2008 Jazz Pharmaceuticals, Inc.
